Chronic myeloid leukemia: the paradigm of targeting oncogenic tyrosine kinase signaling and counteracting resistance for successful cancer therapy

Cobll1 is linked to drug resistance and blastic transformation in chronic myeloid leukemia

(2017) S H Han et al.   LEUKEMIA

Differential signaling through p190 and p210 BCR-ABL fusion proteins revealed by interactome and phosphoproteome analysis

(2017) J A Cutler et al.   LEUKEMIA

Differential signaling networks of Bcr–Abl p210 and p190 kinases in leukemia cells defined by functional proteomics

(2017) S Reckel et al.   LEUKEMIA

The allosteric inhibitor ABL001 enables dual targeting of BCR–ABL1

(2017) Andrew A. Wylie et al.   NATURE

Current Issues in Chronic Myeloid Leukemia: Monitoring, Resistance, and Functional Cure

(2017) Jorge Cortes et al.   Journal of the National Comprehensive Cancer Network

Spectrum of somatic mutation dynamics in chronic myeloid leukemia following tyrosine kinase inhibitor therapy

(2016) TaeHyung Kim et al.   BLOOD

Moving treatment-free remission into mainstream clinical practice in CML

(2016) Timothy P. Hughes et al.   BLOOD

Axl Blockade by BGB324 Inhibits BCR-ABL Tyrosine Kinase Inhibitor–Sensitive and -Resistant Chronic Myeloid Leukemia

(2016) Isabel Ben-Batalla et al.   CLINICAL CANCER RESEARCH

Allosteric Inhibition of Bcr-Abl Kinase by High Affinity Monobody Inhibitors Directed to the Src Homology 2 (SH2)-Kinase Interface

(2016) John Wojcik et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

A role for FOXO1 in BCR–ABL1-independent tyrosine kinase inhibitor resistance in chronic myeloid leukemia

(2016) M Wagle et al.   LEUKEMIA

The concept of treatment-free remission in chronic myeloid leukemia

(2016) S Saußele et al.   LEUKEMIA

T315L: a novel mutation within BCR-ABL kinase domain confers resistance against ponatinib

(2016) Dongmei Wang et al.   LEUKEMIA & LYMPHOMA

Natural course and biology of CML

(2015) Bradley Chereda et al.   ANNALS OF HEMATOLOGY

shRNA library screening identifies nucleocytoplasmic transport as a mediator of BCR-ABL1 kinase-independent resistance

(2015) J. S. Khorashad et al.   BLOOD

Compound mutations in BCR-ABL1 are not major drivers of primary or secondary resistance to ponatinib in CP-CML patients

(2015) M. W. Deininger et al.   BLOOD

Mutations in the BCR-ABL1 Kinase Domain and Elsewhere in Chronic Myeloid Leukemia

(2015) Simona Soverini et al.   Clinical Lymphoma Myeloma & Leukemia

β-Catenin is required for intrinsic but not extrinsic BCR-ABL1 kinase-independent resistance to tyrosine kinase inhibitors in chronic myeloid leukemia

(2015) A M Eiring et al.   LEUKEMIA

Expression of LYN and PTEN genes in chronic myeloid leukemia and their importance in therapeutic strategy

(2014) Cristian Ferri et al.   BLOOD CELLS MOLECULES AND DISEASES

BCR-ABL1 Compound Mutations Combining Key Kinase Domain Positions Confer Clinical Resistance to Ponatinib in Ph Chromosome-Positive Leukemia

(2014) Matthew S. Zabriskie et al.   CANCER CELL

Kinase-inhibitor–insensitive cancer stem cells in chronic myeloid leukemia

(2014) Alessandro Morotti et al.   EXPERT OPINION ON BIOLOGICAL THERAPY

Measurement of adherence to BCR-ABL inhibitor therapy in chronic myeloid leukemia: current situation and future challenges

(2014) L. Noens et al.   HAEMATOLOGICA

Combined STAT3 and BCR-ABL1 inhibition induces synthetic lethality in therapy-resistant chronic myeloid leukemia

(2014) A M Eiring et al.   LEUKEMIA

Molecular-defined clonal evolution in patients with chronic myeloid leukemia independent of the BCR-ABL status

(2014) M Schmidt et al.   LEUKEMIA

The Capable ABL: What Is Its Biological Function?

(2014) J. Y. J. Wang   MOLECULAR AND CELLULAR BIOLOGY

Incidence of bcr-abl fusion transcripts in healthy individuals

(2014) SAID I. ISMAIL et al.   Molecular Medicine Reports

Identification of pre-leukaemic haematopoietic stem cells in acute leukaemia

(2014) Liran I. Shlush et al.   NATURE

Age-related mutations associated with clonal hematopoietic expansion and malignancies

(2014) Mingchao Xie et al.   NATURE MEDICINE

Clonal Hematopoiesis and Blood-Cancer Risk Inferred from Blood DNA Sequence

(2014) Giulio Genovese et al.   NEW ENGLAND JOURNAL OF MEDICINE

Age-Related Clonal Hematopoiesis Associated with Adverse Outcomes

(2014) Siddhartha Jaiswal et al.   NEW ENGLAND JOURNAL OF MEDICINE

ABCB1 polymorphisms predict imatinib response in chronic myeloid leukemia patients: a systematic review and meta-analysis

(2014) Q Zheng et al.   PHARMACOGENOMICS JOURNAL

Molecular dynamics reveal BCR-ABL1 polymutants as a unique mechanism of resistance to PAN-BCR-ABL1 kinase inhibitor therapy

(2014) Don L. Gibbons et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013

(2013) M. Baccarani et al.   BLOOD

Unraveling the complexity of tyrosine kinase inhibitor-resistant populations by ultra-deep sequencing of the BCR-ABL kinase domain

(2013) S. Soverini et al.   BLOOD

Analysis of BCR/ABL transcripts in healthy individuals

(2013) J.A. Boquett et al.   GENETICS AND MOLECULAR RESEARCH

Structure and Dynamic Regulation of Abl Kinases

(2013) Shoghag Panjarian et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Implications of BCR-ABL1 kinase domain-mediated resistance in chronic myeloid leukemia

(2013) Simona Soverini et al.   LEUKEMIA RESEARCH

Expression of BCR/ABL p210 from a Knockin Allele Enhances Bone Marrow Engraftment without Inducing Neoplasia

(2013) Samantha B. Foley et al.   Cell Reports

Chronic myeloid leukemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

(2012) M. Baccarani et al.   ANNALS OF ONCOLOGY

BCR-ABL1 compound mutations in tyrosine kinase inhibitor-resistant CML: frequency and clonal relationships

(2012) J. S. Khorashad et al.   BLOOD

Investigating factors associated with adherence behaviour in patients with chronic myeloid leukemia: an observational patient-centered outcome study

(2012) F Efficace et al.   BRITISH JOURNAL OF CANCER

Association between imatinib transporters and metabolizing enzymes genotype and response in newly diagnosed chronic myeloid leukemia patients receiving imatinib therapy

(2012) S. Angelini et al.   HAEMATOLOGICA

Advances in treatment of chronic myeloid leukemia with tyrosine kinase inhibitors: the evolving role of Bcr–Abl mutations and mutational analysis

(2012) Simona Soverini et al.   PHARMACOGENOMICS

Nonadherence to Imatinib adversely affects event free survival in chronic phase chronic myeloid leukemia

(2011) Prasanth Ganesan et al.   AMERICAN JOURNAL OF HEMATOLOGY

BCR-ABL kinase domain mutation analysis in chronic myeloid leukemia patients treated with tyrosine kinase inhibitors: recommendations from an expert panel on behalf of European LeukemiaNet

(2011) S. Soverini et al.   BLOOD

Targeting the SH2-Kinase Interface in Bcr-Abl Inhibits Leukemogenesis

(2011) Florian Grebien et al.   CELL

Common Leukemia- and Lymphoma-Associated Genetic Aberrations in Healthy Individuals

(2011) Jianbo Song et al.   JOURNAL OF MOLECULAR DIAGNOSTICS

Choosing the Best Second-Line Tyrosine Kinase Inhibitor in Imatinib-Resistant Chronic Myeloid Leukemia Patients Harboring Bcr-Abl Kinase Domain Mutations: How Reliable Is the IC50?

(2011) S. Soverini et al.   ONCOLOGIST

Structural Mechanism of the Pan-BCR-ABL Inhibitor Ponatinib (AP24534): Lessons for Overcoming Kinase Inhibitor Resistance

(2010) Tianjun Zhou et al.   Chemical Biology & Drug Design

Functional Activity of the OCT-1 Protein Is Predictive of Long-Term Outcome in Patients With Chronic-Phase Chronic Myeloid Leukemia Treated With Imatinib

(2010) Deborah L. White et al.   JOURNAL OF CLINICAL ONCOLOGY

Targeting Bcr–Abl by combining allosteric with ATP-binding-site inhibitors

(2010) Jianming Zhang et al.   NATURE

Nilotinib concentration in cell lines and primary CD34+ chronic myeloid leukemia cells is not mediated by active uptake or efflux by major drug transporters

(2009) A Davies et al.   LEUKEMIA

Multidrug resistance gene (MDR1) polymorphisms are associated with major molecular responses to standard-dose imatinib in chronic myeloid leukemia

(2008) S. Dulucq et al.   BLOOD

Dasatinib Cellular Uptake and Efflux in Chronic Myeloid Leukemia Cells: Therapeutic Implications

(2008) D. K. Hiwase et al.   CLINICAL CANCER RESEARCH

Imatinib mesylate for the treatment of chronic myeloid leukemia

(2008) Simona Soverini et al.   Expert Review of Anticancer Therapy

Mathematical Models of Cancer Stem Cells

(2008) Franziska Michor   JOURNAL OF CLINICAL ONCOLOGY

Association Between Imatinib-Resistant BCR-ABL Mutation-Negative Leukemia and Persistent Activation of LYN Kinase

(2008) Ji Wu et al.   JNCI-Journal of the National Cancer Institute

Global target profile of the kinase inhibitor bosutinib in primary chronic myeloid leukemia cells

(2008) L L Remsing Rix et al.   LEUKEMIA